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Introduction
Adrenomedullin (AM) is a potent vasodilator and natriuretic, diuretic peptide that was originally identified from human pheochromocytoma (1) . AM belongs to the calcitonin generelated peptide (CGRP) family, whose other members are also known to be strong vasodilators. High levels of AM are found in the heart, lung, kidney, and vascular endothelial and smooth muscle cells, as well as in the adrenal medulla (2) (3) (4) (5) . Although AM appears to act in a local paracrine and/or autocrine fashion within the tissue of origin, it also circulates in plasma and has been shown to act as a regulator of the cardiovascular system. AM induces dose-dependent blood pres-II) (14) . Whether or not AM is involved in the development of cardiac hypertrophy and renal damage remains to be clarified.
We recently generated AM knockout mice in order to better understand the physiological roles of AM in vivo. Homozygous mice (AM / ) died in utero at embryonic day 13.5 (15) . Heterozygotes (AM / ), on the other hand, survived until adulthood and were apparently normal and fertile, although they did exhibit elevated blood pressure. We here demonstrate that the AM reduction in AM knockout mice resulted in severe cardiac hypertrophy and further renal damage in response to stressors.
Methods Animals
Twelve-week-old male AM / mice (n 42) and AM / mice (n 38) from the same genetic background were used in the present study. Mice were housed under climate-controlled conditions with a 12-h light/dark cycle and were provided with standard food and water. All experiments were performed in accordance with the Declaration of Helsinki and were approved by the University of Tokyo Ethics Committee for Animal Experiments.
Angiotensin II-Infusion Model
An osmotic minipump (model 2002; Alzet Corp., Palo Alto, USA) containing Ang II dissolved in 0.15 mol/l NaCl and 1 mmol/l acetic acid was implanted subcutaneously into the mice. The delivery rate was 3.2 mg/kg per day for 14 days. After 14 days, the hearts and kidneys were removed, weighed and subjected to further analysis.
Physiological Studies
Systolic blood pressure (SBP) and heart rate were determined before and 7 and 14 days after the drug infusion using a programmable sphygmomanometer connected to a cuff probe for mice (MCP-1; Softron, Tokyo, Japan) as described previously (16) . Ten repeated values were averaged at each determination. This noninvasive method to measure blood pressure has been validated in mice and correlates well with intra-arterial measurements made in normotensive and hypertensive mice; in addition, it requires minimal warming of the mice (usually less than 15 min) before blood pressure measurement.
Transthoracic echocardiography was performed with an HP Sonos 100 (Hewlett-Packard Co., Palo Alto, USA) using a 12 MHz imaging transducer as described previously (17, 18) . After a good-quality two-dimensional image was obtained, M-mode images of the left ventricle were recorded. Intraventricular septum thickness (IVST) and ejection fraction (EF) were also measured.
Histological Analysis
For histological analysis, hearts and kidneys were fixed with 10% formalin by perfusion fixation. Fixed hearts and kidneys embedded in paraffin were sectioned at 4-µm thickness and Masson trichrome staining was performed. In the kidney, the glomerular injury scores were graded as follows: 0, no changes; 1, lesions involving 25% of the capillary tuft; 2, lesions involving 25-49% of the capillary tuft; 3, lesions involving 50-75% of the capillary tuft; 4, lesions involving 75% of the capillary tuft. The resulting index in each animal was expressed as a mean of all scores obtained. All sections used were evaluated under blind conditions without prior knowledge as to which section belonged to which mouse.
Serum and Urine Laboratory Analyses
Ten to 14 days after the osmotic minipumps containing Ang II were implanted, mice were housed in metabolic cages for 24-h urine collection. Urine volume and water intake were recorded, and then the urine samples were assayed for creatinine (Cr). At 14 days, blood was collected to measure Cr, and then creatinine clearance (Ccr) was calculated.
Statistics
Differences within groups were compared by one-way analysis of variance (ANOVA) and Student's t-test. Values of p 0.05 were considered to indicate statistical significance.
Results

Characterization of AM Knockout Mice
Targeted null mutation of the AM gene in utero is lethal. The mortality rate among AM / embryos was over 80% at embryonic day 13.5. The most apparent abnormality in AM / embryos was severe hemorrhage, readily observable under the skin and in visceral organs (15) . In contrast, AM / mice survived until adulthood and were apparently normal and fertile.
Changes in Blood Pressure by Ang II Infusion
We have reported that arterial blood pressure, directly measured by means of a catheter inserted into the femoral artery, was about 10 mmHg higher in AM / mice compared with their wild-type littermates (15) . Before treatment in the present study, AM / mice also tended to have higher blood pressure as measured by a programmable sphygmomanometer, but the difference was not significant. Nearly the same degree of blood pressure elevation was observed in both AM / and wild-type mice, and no significant difference in blood pressure was observed between the two groups at the 14th day, the end point of the study (Fig. 1) .
Severe Cardiac Hypertrophic Changes in AM / Mice
At 14 days after Ang II infusion, the heart weight-to-body weight ratio increased significantly in both AM / and AM / mice, although the increase was more prominent in the AM / mice (Fig. 2) . We also evaluated morphometrical and functional changes after Ang II infusion using echocardiography (Fig. 3) . IVST was significantly thicker in AM / mice than in AM / mice after Ang II infusion (AM / , 1.06 0.14 mm; AM / , 1.16 0.09 mm; p 0.01; n 18) (Fig. 3A) . In contrast, EF was significantly lower in AM / mice both before and after Ang II infusion (before: AM / , 0.94 0.11; AM / , 0.89 0.05; p 0.05; after: AM / , 0.93 0.05; AM / , 0.87 0.06; p 0.05; n 18) (Fig. 3B) .
Severe Renal Damage in AM / Mice
Urine volume was significantly lower in AM / mice compared with their wild-type littermates. Continuous infusion of Ang II markedly increased urine volume and water intake in both strains of mice. However, the increases in both urine volume and water intake were significantly lower in the AM / mice compared with their wild-type littermates (Fig. 4) .
Glomerular sclerosis was more severe and glomerular injury score was significantly higher in AM / mice compared with the wild-type mice (Fig. 5A, B) . Ccr was significantly lower in AM / mice (Fig. 5C ).
Discussion
It has been reported that AM plays important roles in cardiac and renal function in addition to blood pressure regulation (7, 8) . Plasma levels of AM peptide are increased in hypertensive animal models, which may indicate that AM participates in a mechanism to counteract high blood pressure (19) . In addition, increased levels of locally synthesized and systemic plasma AM may also compensate for or prevent damage in target tissues, such as the heart and kidney, as well as in the vasculature (20) (21) (22) . We previously showed that transgenic mice overexpressing AM developed significantly lower blood pressure compared with their wild-type littermates (23) . After induction of lipopolysaccharide shock, AM transgenic mice exhibited a smaller decline in blood pressure, less severe organ damage, and higher 24-h survival rates. Taken together, these results indicate that the enhancement of systemic and/or local AM systems may play an important role in the attenuation of cardiovascular and renal damage.
We applied an Ang II-infusion model using AM knockout mice to further evaluate in vivo function in the presence of cardiorenal diseases. Continuous Ang II infusion has been shown to cause cardiac hypertrophy and renal dysfunction in animal models (24, 25) . In the basal state in the present study, there was no significant difference in the ratios of heart and kidney weight-to-body weight between AM / mice and their wild-type littermates. In contrast, Ang II infusion induced more marked hypertrophic responses, including increases in heart weight and left ventricle wall thickness in AM / mice compared with wild-type mice. This result clearly indicates that AM is critically involved in the development of cardiac hypertrophy. However, the mechanism by which AM is involved in the prevention of cardiac hypertrophy is still unclear. We have reported that AM protects renal tissues from ischemia/reperfusion injury through its nitric oxide (NO)-releasing activity, based on the finding that the increase in severity of renal damage observed in AM / mice relative to wild-type mice was canceled when they were pretreated with N G -nitro-L-arginine methyl ester (L-NAME), an inhibitor of NO synthase (20) . In contrast, the preventive effect of AM against cardiac hypertrophy was not likely to have been mediated by NO in this study. In our preliminary study, treatment of L-NAME (dissolved in the drinking water at a concentration of 200 mg/l) could not cancel the difference of cardiac hypertrophy caused by Ang II infusion. In mesangial cells, it has been shown that AM increases cAMP and causes a protein kinase A-dependent decrease in proliferation and an increase in apoptosis, which effects are associated with decreases in extracellular signal-regulated kinase (ERK) activities (26) . ERKs also play important roles in the development of cardiac hypertrophy (27, 28) . AM may be involved in the regulation of ERK activity, and thereby contribute to the prevention of cardiac hypertrophy.
Fig. 3. Comparison of (A) intraventricular septum thickness (IVST) and (B) ejection fraction (EF
In this study, we also showed that the increases in urine volume and water intake were significantly lower in the AM / mice compared with the wild-type mice after Ang II infusion. Furthermore, Ccr was significantly lower, and glomerular injury score was significantly higher, in AM / mice. It has been reported that intrarenal infusion of AM induced dose-dependent increases in renal blood flow, urine flow, and urinary sodium excretion (29) . Previous studies have also reported that exogenous AM infusion or AM gene delivery improved renal function (30) (31) (32) . Our present results demonstrate that endogenous AM actually plays critical roles in the prevention of renal damage. In addition, AM may have beneficial hemodynamic effects and may promote maintenance or improvement in renal function.
Proadrenomedullin N-terminal 20 peptide (PAMP) is a bioactive peptide derived from the N-terminal portion of the proAM peptide, the precursor of AM (33) . In our gene-targeting procedure, the PAMP-coding region was also deleted.
PAMP has been shown to inhibit catecholamine release from synthetic nerve endings and adrenal medullary cells (34) . However, the role of PAMP in the heart and kidney remains unclear and should be further investigated. CGRP and AM share common structural characteristics and receptors and belong to the same peptide family. We have also established CGRP / mice (35) . While AM / mice did not survive beyond midgestation, CGRP / mice survived until adulthood and demonstrated increased sympathetic activity. Thus, targeted disruption of AM and CGRP genes reveals their distinct biological roles (36) .
In this study, we have demonstrated that AM reduction induced severe cardiac hypertrophy and renal damage under stress, suggesting that AM may play important roles in safeguarding against organ damage, and providing evidence for the potential use of AM as a candidate for the treatment of cardiovascular and renal diseases. 
